Does Xopenex Raise Heart Rate?
Yes, Xopenex (levalbuterol) does raise heart rate, as this is a well-established adverse effect of all beta-adrenergic agonist bronchodilators, though the clinical significance is generally minimal in most patients.
Mechanism and FDA-Confirmed Effects
Levalbuterol, like all short-acting beta-agonists (SABAs), causes tachycardia through beta-adrenergic receptor stimulation. The FDA drug label explicitly lists "rapid heart rate" as a common adverse effect of Xopenex 1. The label warns that the medication can produce "clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms" 1.
Clinical Evidence on Heart Rate Changes
The magnitude of heart rate increase is modest and generally well-tolerated:
In healthy adults: Levalbuterol causes a median 23% increase in heart rate from baseline (IQR 19-31%), which is statistically less than albuterol's 30% increase (IQR 19-43%), though the clinical difference is minimal 2
In pediatric cardiology patients: Levalbuterol increases heart rate by an average of 6.2 beats/min, essentially equivalent to racemic albuterol's 6.8 beats/min increase 3
In PICU patients: No significant difference in heart rate changes between levalbuterol and albuterol during continuous nebulization 4
In hyperkalemic patients: Both medications show similar heart rate patterns over time with no significant difference at 30 minutes 5
Comparison to Albuterol
The original rationale for using levalbuterol was to reduce cardiovascular side effects compared to racemic albuterol, but this advantage has not been clinically substantiated. National guidelines state that levalbuterol has "an effectiveness and side effect profile indistinguishable from that of the racemic mixture of molecules in albuterol" 6. The NAEPP guidelines confirm that tachycardia is a potential adverse effect common to all SABAs, including both albuterol and levalbuterol 7.
Clinical Implications and Precautions
Use with caution in patients with:
- Coronary insufficiency
- Cardiac arrhythmias
- Hypertension
- Hyperthyroidism
- Patients unusually responsive to sympathomimetic amines 1
Key clinical pitfalls to avoid:
- Don't assume levalbuterol is "safer" for the heart than albuterol—the evidence doesn't support meaningful clinical differences in cardiovascular effects
- The tachycardia is typically dose-dependent and transient
- Most patients tolerate the heart rate increase well, but monitor closely in those with cardiovascular disease
- Beta-blockers may diminish effectiveness but are not absolutely contraindicated 6
Bottom Line for Practice
Xopenex will raise heart rate in most patients as an expected pharmacologic effect. This increase is generally clinically insignificant in patients without cardiovascular disease. If you're considering levalbuterol specifically to avoid tachycardia, reconsider—it offers no meaningful advantage over albuterol for this purpose and costs significantly more 6, 8.